Form 8-K - Current report:
SEC Accession No. 0001558370-24-013486
Filing Date
2024-10-23
Accepted
2024-10-23 09:00:25
Documents
17
Period of Report
2024-10-23
Items
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K apre-20241023x8k.htm   iXBRL 8-K 41143
2 EX-99.1 apre-20241023xex99d1.htm EX-99.1 25698
3 GRAPHIC apre-20241023xex99d1001.jpg GRAPHIC 8832
  Complete submission text file 0001558370-24-013486.txt   243658

Data Files

Seq Description Document Type Size
4 EX-101.SCH apre-20241023.xsd EX-101.SCH 4371
5 EX-101.DEF apre-20241023_def.xml EX-101.DEF 2849
6 EX-101.LAB apre-20241023_lab.xml EX-101.LAB 12250
7 EX-101.PRE apre-20241023_pre.xml EX-101.PRE 11776
19 EXTRACTED XBRL INSTANCE DOCUMENT apre-20241023x8k_htm.xml XML 4907
Mailing Address 3805 OLD EASTON ROAD DOYLESTOWN PA 18902
Business Address 3805 OLD EASTON ROAD DOYLESTOWN PA 18902 617-463-9385
Aprea Therapeutics, Inc. (Filer) CIK: 0001781983 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39069 | Film No.: 241387901
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)